Theyconcluded the impact of this change as “particularly important with vascularendothelial growth factor-targeted agents” such as cediranib.26 It is our belief that these changes would not have altered the overalltoxicity assessment as the changes were not biased toward one arm, it was alreadyacknowledged that the toxic effects of vascular endothelial growth factor inhibitorscan be problematic, and prompt management guidelines were generally successful incontrolling further hypertension. This evidence concerns the gene VEGFA and Hypertension.